Spero Therapeutics
Spero Therapeutics is dedicated to advancing new therapies for patients with rare diseases and multidrug-resistant bacterial infections. The company focuses on developing innovative treatments to address high unmet medical needs, aiming to bring hope to patients and families affected by serious infections and rare conditions.
Industries
Nr. of Employees
small (1-50)
Spero Therapeutics
Patents
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
US-12098155-B2
View DetailsTebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
US-11718621-B2
View Details
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
US-12098155-B2
View DetailsTebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
US-11718621-B2
View DetailsProducts
Investigational oral carbapenem candidate for complicated urinary tract infections
Orally administered carbapenem-class antibacterial candidate intended to provide an oral alternative to intravenous carbapenems for complicated urinary tract infection and acute pyelonephritis.
Oral gyrase B–targeting antibacterial candidate for nontuberculous mycobacterial pulmonary disease
Oral prodrug converted in vivo to an active gyrase B/topoisomerase ATPase inhibitor evaluated for NTM pulmonary disease; includes preclinical activity against NTM species and early clinical PK/safety evaluation.
Investigational oral carbapenem candidate for complicated urinary tract infections
Orally administered carbapenem-class antibacterial candidate intended to provide an oral alternative to intravenous carbapenems for complicated urinary tract infection and acute pyelonephritis.
Oral gyrase B–targeting antibacterial candidate for nontuberculous mycobacterial pulmonary disease
Oral prodrug converted in vivo to an active gyrase B/topoisomerase ATPase inhibitor evaluated for NTM pulmonary disease; includes preclinical activity against NTM species and early clinical PK/safety evaluation.
Services
Design and conduct of Phase 1–3 clinical studies for antibacterial candidates, including protocol development, enrollment oversight, IDMC-managed interim analyses, and data generation for regulatory submissions.
Development and validation of in vitro susceptibility assays, MIC determination methods for automated panels, and activity testing against surveillance and clinical isolate collections.
Execution of in vitro and in vivo PK/PD experiments (including hollow-fiber models), mechanism-of-action assays, and resistance characterization studies to support candidate progression.
Retrospective database analyses, cost-of-illness studies, and epidemiological surveillance to quantify burden, antibiotic utilization, and economic impact.
Structuring and managing strategic collaborations, licensing agreements, and partnerships with government agencies, academic centers, and industry partners to advance development and commercialization.
Design and conduct of Phase 1–3 clinical studies for antibacterial candidates, including protocol development, enrollment oversight, IDMC-managed interim analyses, and data generation for regulatory submissions.
Development and validation of in vitro susceptibility assays, MIC determination methods for automated panels, and activity testing against surveillance and clinical isolate collections.
Execution of in vitro and in vivo PK/PD experiments (including hollow-fiber models), mechanism-of-action assays, and resistance characterization studies to support candidate progression.
Retrospective database analyses, cost-of-illness studies, and epidemiological surveillance to quantify burden, antibiotic utilization, and economic impact.
Structuring and managing strategic collaborations, licensing agreements, and partnerships with government agencies, academic centers, and industry partners to advance development and commercialization.
Expertise Areas
- Antibacterial drug development (oral and systemic agents)
- Clinical trial management for anti-infectives, including non-inferiority designs
- Regulatory strategy and FDA interactions for antimicrobial programs
- Microbiology and antimicrobial susceptibility testing method development
Key Technologies
- Hollow-fiber in vitro infection models for PK/PD
- Murine and other in vivo infection models
- Next-generation MIC susceptibility testing and automated dried‑panel assays
- Structure-guided drug design and SAR optimization
News & Updates
The trial met its primary endpoint, demonstrating non-inferiority to intravenous imipenem-cilastatin, and will be submitted to the FDA in 2H 2025.
The company reported its financial results and provided updates on its business activities.
Leadership change announcement.
Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections
Research on Tebipenem hydrolysis by β-Lactamases, published in Antimicrobial Agents and Chemotherapy, May 2022.
Study on the economic impact of complicated UTIs in Medicare patients, published in Antibiotics, 2022.
Research on pharmacokinetics of tebipenem in urine, published in Journal of Antimicrobial Chemotherapy, 2022.
The trial met its primary endpoint, demonstrating non-inferiority to intravenous imipenem-cilastatin, and will be submitted to the FDA in 2H 2025.
The company reported its financial results and provided updates on its business activities.
Leadership change announcement.
Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections
Research on Tebipenem hydrolysis by β-Lactamases, published in Antimicrobial Agents and Chemotherapy, May 2022.
Study on the economic impact of complicated UTIs in Medicare patients, published in Antibiotics, 2022.
Research on pharmacokinetics of tebipenem in urine, published in Journal of Antimicrobial Chemotherapy, 2022.